| Id |
Subject |
Object |
Predicate |
Lexical cue |
| T213 |
0-93 |
Sentence |
denotes |
• Heparin anticoagulant treatment in sepsis-induced coagulopathy • Retrospective cohort study |
| T214 |
94-113 |
Sentence |
denotes |
• ≥ 18 years of age |
| T215 |
114-141 |
Sentence |
denotes |
• Severe COVID-19 infection |
| T216 |
142-207 |
Sentence |
denotes |
• Evaluation of 28-day mortality in heparin and non-heparin users |
| T217 |
208-258 |
Sentence |
denotes |
• 48.5% comorbid hypertension and/or heart disease |
| T218 |
259-276 |
Sentence |
denotes |
• N = 99 heparin |
| T219 |
277-502 |
Sentence |
denotes |
• N = 350 no heparin • Unfractionated (10, 000–15, 000 U/day) or low molecular weight heparin (40–60 mg enoxaparin/day) for 7 days or longer • No difference in 28-day mortality endpoint between heparin and non-heparin users. |
| T220 |
503-613 |
Sentence |
denotes |
• Lower 28-day mortality in patients with sepsis-induced coagulopathy (SIC) score of ≥4 in stratified analysis |
| T221 |
614-829 |
Sentence |
denotes |
• Odd Ratio (OR) 0.372 (95% CI 0.154–0.901) • Heparin may be associated with a lower 28-day mortality rate only in patients with enhanced coagulopathy risk such as SIC score of 4 or greater (Tang, Bai, et al., 2020) |
